Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
S. Targan, S.B. Hanauer, Daventer SJH Van, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
N Engl J Med, 337 (1997), pp. 1029-1035
[2.]
P. Rutgeerts, G. D'Haens, S. Targan, et al.
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology, 17 (1999), pp. 761-769
[3.]
D.H. Present, P. Rutgeerts, S. Targan, et al.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[4.]
S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Lancet, 359 (2002), pp. 1541-1549
[5.]
B.E. Sands, W.J. Tremaine, W.J. Sandborn, et al.
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
Infl Bowel Dis, 7 (2001), pp. 83-88
[6.]
C.S.J. Probert, S.D. Hearing, S. Schreiber, et al.
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.
Gut, 52 (2003), pp. 998-1002
[7.]
T. Ochsenkun, M. Sackmann, B. Goeke.
Infliximab for acute severe ulcerative colitis: a randomized pilot study in non steroid refractory patients.
Gastroenterology, 124 (2003), pp. A62
[8.]
E. Domènech, M. Esteve-Comas, F. Gomollón, et al.
Recomendaciones para el uso de infliximab (RemicadeR) en la enfermedad de Crohn. GETECCU 2001.
Gastroenterol Hepatol, 25 (2002), pp. 162-169
[9.]
W.J. Sandborn, S.B. Hanauer.
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Am J Gastroenterol, 97 (2002),
[10.]
J. Keane, S. Gershon, R.P. Wise, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[11.]
A. Obrador, A. López San Román, P. Muñoz, et al.
Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab.
Gastroenterol Hepatol, 26 (2003), pp. 29-33
[12.]
S. Lori Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, M. Miles Braun.
Tumor necrosis factor antagonist therapy and lymphoma development.
Arthr Rheum, 46 (2002), pp. 3151-3158
[13.]
E. Garcia-Planella, E. Domènech, M. Esteve-Comas, et al.
Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab).
Eur J Gastroenterol Hepatol, 15 (2003), pp. 1-4
[14.]
S. Vermeire, M. Noman, G. Van Assche, et al.
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Gastroenterology, 125 (2003), pp. 32-39
[15.]
F. Baert, M. Noman, S. Vermeire, et al.
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
N Engl J Med, 348 (2003), pp. 601-608
[16.]
R.J. Farrell, M. Alsahli, Y-T Jeen, K.R. Falchuk, M.A. Peppercorn, P. Michetti.
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial.
Gastroenterology, 124 (2003), pp. 917-924
[17.]
W.J. Sandborn.
Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize.
Gastroenterlogy, 124 (2003), pp. 1140-1145
[18.]
S. Kugathasan, M.B. Levy, K. Saeian, et al.
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
Am J Gastroenterol, 97 (2002), pp. 1408-1414
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
